Emerging Roles for Ion Channels in Ovarian Cancer: Pathomechanisms and Pharmacological Treatment
Overview
Authors
Affiliations
Ovarian cancer (OC) is the deadliest gynecologic cancer, due to late diagnosis, development of platinum resistance, and inadequate alternative therapy. It has been demonstrated that membrane ion channels play important roles in cancer processes, including cell proliferation, apoptosis, motility, and invasion. Here, we review the contribution of ion channels in the development and progression of OC, evaluating their potential in clinical management. Increased expression of voltage-gated and epithelial sodium channels has been detected in OC cells and tissues and shown to be involved in cancer proliferation and invasion. Potassium and calcium channels have been found to play a critical role in the control of cell cycle and in the resistance to apoptosis, promoting tumor growth and recurrence. Overexpression of chloride and transient receptor potential channels was found both in vitro and in vivo, supporting their contribution to OC. Furthermore, ion channels have been shown to influence the sensitivity of OC cells to neoplastic drugs, suggesting a critical role in chemotherapy resistance. The study of ion channels expression and function in OC can improve our understanding of pathophysiology and pave the way for identifying ion channels as potential targets for tumor diagnosis and treatment.
Extracellular Regucalcin: A Potent Suppressor in the Cancer Cell Microenvironment.
Yamaguchi M Cancers (Basel). 2025; 17(2).
PMID: 39858022 PMC: 11763602. DOI: 10.3390/cancers17020240.
Molecular landscape of borderline ovarian tumours: A systematic review.
Sadlecki P, Walentowicz-Sadlecka M Open Med (Wars). 2024; 19(1):20240976.
PMID: 38859878 PMC: 11163159. DOI: 10.1515/med-2024-0976.
Regucalcin Is a Potential Regulator in Human Cancer: Aiming to Expand into Cancer Therapy.
Yamaguchi M Cancers (Basel). 2023; 15(22).
PMID: 38001749 PMC: 10670417. DOI: 10.3390/cancers15225489.
Calcium signals and potential therapy targets in ovarian cancer (Review).
Deng F, Fu M, Zhao C, Lei J, Xu T, Ji B Int J Oncol. 2023; 63(5).
PMID: 37711071 PMC: 10552713. DOI: 10.3892/ijo.2023.5573.
Sanchez-Sandoval A, Hernandez-Plata E, Gomora J Front Pharmacol. 2023; 14:1206136.
PMID: 37456756 PMC: 10348687. DOI: 10.3389/fphar.2023.1206136.